CHICAGO, March 8, 2019 /PRNewswire/ -- Jeff Aronin, Chairman and CEO of Paragon Biosciences, has been awarded the 2019 BIG Innovation Award. The Business Intelligence Group presents this award to honor executives who improve quality of life with their leadership and business strategies.
Maria Jimenez, Chief Operating Officer of the Business Intelligence Group, announced: "This year's winners show just how deep a role innovation plays in nearly every aspect of business. We are thrilled to be honoring Jeff Aronin as he is leading by example and making real progress on improving the daily lives of so many."
Throughout his career, Aronin's companies have focused on developing therapies for patients who suffer from severe and debilitating medical conditions. That commitment to patients' critical needs continues at Paragon Biosciences. All of Paragon's portfolio companies are developing potential therapies for severe medical conditions which do not yet have adequate treatments.
Paragon's contribution of Bioscience Innovation Capital™ consists of viability assessment of potential therapies, financing of new biopharmaceutical companies to develop those therapies, and early incubation services to its portfolio companies ranging from turnkey IT systems to clinical and regulatory guidance.
After being presented with the BIG Innovation Award, Jeff Aronin said: "The Paragon Biosciences team prides itself on our commitment to solving critical medical needs that are underserved by others. The BIG Innovation Award is a testament to the Bioscience Innovation Capital™ we contribute and my team's dedication to improving lives."
Jeff Aronin has been a leader in the healthcare industry for over two decades. The BIG Innovation Award is the most recent of the many honors that Aronin has earned for his leadership in the development of novel therapies. Insights Care magazine also recently named Aronin as one of the most influential leaders in healthcare for his impressive track record of developing important therapies which help people live longer, healthier lives.
About Paragon Biosciences:
For rare and complex diseases, Paragon Biosciences researches the viability of potential treatments for unmet patient needs, invests in the development of novel medicines, launches biopharmaceutical companies to further develop those therapies, and supports these new portfolio companies with early-incubation services. After which, the portfolio companies operate independently as they conduct clinical trials and seek FDA approval of improved treatments. Paragon Biosciences is headquartered in Chicago, Illinois. For more information, visit: ParagonBioSci.com.
About Business Intelligence Group:
The Business Intelligence Group (BIG) was founded with the mission of recognizing true talent and superior performance in the business world. The organization's proprietary and unique scoring system selectively measures performance across multiple business domains and then rewards those whose achievements stand above those of their peers.
SOURCE Paragon Biosciences